Rhinitis Allergic Clinical Trial
Official title:
A Non-controlled, Open Study for Assessing the Safety and Effectiveness of a Twice-daily FEX 60 mg - PE 10 mg (FEX60/PE10) Fixed Combination Tablet in Patients With Allergic Rhinitis
Primary Objective:
To assess the safety of twice-daily fexofenadine 60 mg/phenylephrine 10 mg (FEX60/PE10)
combination tablet in patients with allergic rhinitis.
Secondary Objective:
To evaluate the effectiveness of a twice-daily FEX60/PE10 combination tablet on nasal
symptoms (sneezing, rhinorrhea, and nasal congestion), and daily activity impairment.
It will be 22 days at minimum and up to 32 days depending on screening, treatment, and post-treatment observation allowances. ;
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03317015 -
A Study to Assess Efficacy and Safety of Nasacort® Nasal Spray in Comparison With Flixonase® Nasal Spray in Adults Suffering From Perennial Allergic Rhinitis (PAR)
|
Phase 3 | |
| Completed |
NCT00380705 -
Quality of Life in Asthma and Rhinitis Allergic With Singulair (0476-365)
|
Phase 4 | |
| Completed |
NCT02175485 -
Evaluation of Efficacy of Dellegra in Exposure Unit
|
Phase 4 | |
| Completed |
NCT01385371 -
A Study of SCH 697243 in Participants With Grass Pollen Allergy Symptoms, With or Without Asthma (P08067)
|
Phase 3 | |
| Not yet recruiting |
NCT05720455 -
Study to Assess Safety and Efficacy of Fexofenadine Hydrochloride (HCL) + Pseudoephedrine HCL Fixed Dose Combination in Indian Male and Female Participants With Allergic Rhinitis (AR) Who Are 12 Years and Above
|
Phase 4 | |
| Completed |
NCT00446186 -
MK0476 Study in Adult Patients With Allergic Rhinitis (0476-378)
|
Phase 2 |